Acute cardiac care & resuscitation
Safety and Performance of the Aortix Device in Acute Decompensated Heart Failure and Cardiorenal Syndrome
Authors' conclusion
This pilot study of patients with ADHF, persistent congestion, and worsening renal function due to CRS supports the potential for safely achieving decongestion using IAEP therapy.
Study context
- Population
- Patients with acute decompensated heart failure (ADHF) with cardiorenal syndrome and persistent congestion18 received Aortix therapy
- Participants
- 21 patients
- Comparison
- Within-patient changes post vs pre intra-aortic entrainment pump (IAEP) therapy
- Aortixn = 18
- Outcome
- Within-patient changes with IAEP therapy (post-pre): net fluid loss, CVP, PCWP, serum creatinine, eGFR, dyspnea score
- Follow-up
- Pump therapy 4.6 ± 1.6 days
Methodological detailsmulticentre (n = 14), nonrandomised, pilot
- Multicentre (n = 14)
- Nonrandomised
- Pilot
Main finding
As reported in the abstract
- Net fluid loss
- 10.7 ± 6.5 L (P < 0.001)
- Central venous pressure, change from baseline (median [25th-75th percentile])
- −8.5 mm Hg [−3.5 to −10.0 mm Hg] (P < 0.01)
- Pulmonary capillary wedge pressure, change
- −11.0 mm Hg [−5.0 to −14.0 mm Hg] (P < 0.01)
- Serum creatinine, change
- −0.2 mg/dL [−0.1 to −0.5 mg/dL] (P < 0.01)
- eGFR, change
- +5.0 mL/min/1.73 m² [2.0-9.0 mL/min/1.73 m²]
- Patient-reported dyspnea score, change
- +16 [3-37]
Further findings
Dyspnea scores, natriuretic peptides, renal function · 30 days
- Improvements persisted through 30 days
Original publication
Safety and Performance of the Aortix Device in Acute Decompensated Heart Failure and Cardiorenal Syndrome. JACC Heart Fail. Published 4 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →